SHR-A2009

· Henan Cancer Hospital

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for SHR-A2009, covering 2023-10-23 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC [Phase 3]

See pricing